121 related articles for article (PubMed ID: 16626758)
1. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b.
Lanzillo R; Prinster A; Scarano V; Liuzzi R; Coppola G; Florio C; Salvatore E; Schiavone V; Brunetti A; Muto M; Orefice G; Alfano B; Bonavita V; Brescia Morra V
J Neurol Sci; 2006 Jun; 245(1-2):141-5. PubMed ID: 16626758
[TBL] [Abstract][Full Text] [Related]
2. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
4. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
Flechter S; Vardi J; Finkelstein Y; Pollak L
Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
[TBL] [Abstract][Full Text] [Related]
5. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
6. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF
Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356
[TBL] [Abstract][Full Text] [Related]
7. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
Amato MP; Portaccio E; Goretti B; Zipoli V; Battaglini M; Bartolozzi ML; Stromillo ML; Guidi L; Siracusa G; Sorbi S; Federico A; De Stefano N
Arch Neurol; 2007 Aug; 64(8):1157-61. PubMed ID: 17698706
[TBL] [Abstract][Full Text] [Related]
8. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Lacy M; Hauser M; Pliskin N; Assuras S; Valentine MO; Reder A
Mult Scler; 2013 Nov; 19(13):1765-72. PubMed ID: 23652214
[TBL] [Abstract][Full Text] [Related]
9. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis.
Guerrero AL; Tejero MA; Gutiérrez F; Martín-Polo J; Iglesias F; Laherran E; Martín-Serradilla JI; Merino S
Neurologia; 2011 Apr; 26(3):137-42. PubMed ID: 21163235
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
[TBL] [Abstract][Full Text] [Related]
11. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
12. Clinical consequences of MRI activity in treated multiple sclerosis.
Cadavid D; Kim S; Peng B; Skurnick J; Younes M; Hill J; Wolansky LJ; Cook SD
Mult Scler; 2011 Sep; 17(9):1113-21. PubMed ID: 21613336
[TBL] [Abstract][Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
14. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.
Fischer JS; Priore RL; Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Goodkin DE; Granger CV; Simon JH; Grafman JH; Lezak MD; O'Reilly Hovey KM; Perkins KK; Barilla-Clark D; Schacter M; Shucard DW; Davidson AL; Wende KE; Bourdette DN; Kooijmans-Coutinho MF
Ann Neurol; 2000 Dec; 48(6):885-92. PubMed ID: 11117545
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
16. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
18. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
19. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia].
Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM
Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137
[TBL] [Abstract][Full Text] [Related]
20. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
